Novavax Inc (NVAX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Novavax Inc (NVAX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012230
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax’s clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus, Zika virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and a subsidiary (Novavax AB) in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc (NVAX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Novavax Inc, Medical Devices Deals, 2011 to YTD 2017 10
Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Novavax Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Novavax Enters Into Co-Development Agreement With PATH 12
Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 14
Licensing Agreements 15
Isconova Expands Licensing Agreement With Genocea Biosciences For Infectious Disease Vaccines 15
Isconova Expands Licensing Agreement With Crucell 16
Novavax Enters Into Licensing Agreement With LG Life Sciences 17
Equity Offering 18
Novavax Plans to Raise USD75 Million in Public Offering of Shares 18
Novavax Raises USD201.2 Million in Public Offering of Common Stock 19
Novavax Raises USD115 Million in Public Offering of Shares 21
Novavax Completes Public Offering Of Shares For US$100 Million 23
Novavax Completes Private Placement Of Shares For US$27 Million 24
Novavax Completes Private Placement Of Shares For US$12.2 Million 25
Debt Offering 26
Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 26
Acquisition 28
Novavax Completes Acquisition Of 97.4% Interest In Isconova 28
Isconova Acquires Nordic Vaccine 30
Novavax Inc – Key Competitors 31
Novavax Inc – Key Employees 32
Novavax Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Joint Venture 35
Recent Developments 36
Financial Announcements 36
Nov 07, 2017: Novavax Reports Third Quarter 2017 Financial Results 36
Aug 08, 2017: Novavax Reports Second Quarter 2017 Financial Results 38
May 08, 2017: Novavax Reports First Quarter 2017 Financial Results 40
Feb 27, 2017: Novavax Reports Fourth Quarter and Year-End 2016 Financial Results 41
Nov 09, 2016: Novavax Reports Third Quarter 2016 Financial Results 42
Aug 09, 2016: Novavax Reports Second Quarter 2016 Financial Results 44
May 04, 2016: Novavax Reports First Quarter 2016 Financial Results 46
Feb 29, 2016: Novavax Reports Fourth Quarter and Year-End 2015 Financial Results 48
Corporate Communications 50
Oct 13, 2017: Novavax Announces Leadership Change 50
May 11, 2017: Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine 51
Mar 17, 2016: Novavax Announces Management Promotions 52
Product News 53
06/02/2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program 53
Product Approvals 54
May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults 54
Clinical Trials 55
Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Novavax Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Novavax Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Novavax Inc, Medical Devices Deals, 2011 to YTD 2017 10
Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Novavax Enters Into Co-Development Agreement With PATH 12
Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 14
Isconova Expands Licensing Agreement With Genocea Biosciences For Infectious Disease Vaccines 15
Isconova Expands Licensing Agreement With Crucell 16
Novavax Enters Into Licensing Agreement With LG Life Sciences 17
Novavax Plans to Raise USD75 Million in Public Offering of Shares 18
Novavax Raises USD201.2 Million in Public Offering of Common Stock 19
Novavax Raises USD115 Million in Public Offering of Shares 21
Novavax Completes Public Offering Of Shares For US$100 Million 23
Novavax Completes Private Placement Of Shares For US$27 Million 24
Novavax Completes Private Placement Of Shares For US$12.2 Million 25
Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 26
Novavax Completes Acquisition Of 97.4% Interest In Isconova 28
Isconova Acquires Nordic Vaccine 30
Novavax Inc, Key Competitors 31
Novavax Inc, Key Employees 32
Novavax Inc, Other Locations 34
Novavax Inc, Subsidiaries 34
Novavax Inc, Joint Venture 35

★海外企業調査レポート[Novavax Inc (NVAX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sinclair Pharma Ltd:企業の戦略的SWOT分析
    Sinclair Pharma Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Carillion plc:戦略・SWOT・企業財務分析
    Carillion plc - Strategy, SWOT and Corporate Finance Report Summary Carillion plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Widex AS:企業の戦略的SWOT分析
    Widex AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • ERM Power Ltd (EPW):企業の財務・戦略的SWOT分析
    ERM Power Ltd (EPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • EuroSibEnergo Plc-エネルギー分野:企業M&A・提携分析
    Summary EuroSibEnergo PLC (EuroSibEnergo), a subsidiary of En+ Group is an energy company and producer of hydroelectric power. EuroSibEnergo generates, transmits and distributes electricity. It operations include extraction of coal, distribution and facilitating low cost operations. The company is e …
  • NextEra Energy Inc (NEE):企業の財務・戦略的SWOT分析
    NextEra Energy Inc (NEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • OraSure Technologies Inc (OSUR):企業の財務・戦略的SWOT分析
    OraSure Technologies Inc (OSUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Mitsubishi Electric Corporation:企業のM&A・事業提携・投資動向
    Mitsubishi Electric Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitsubishi Electric Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • CK Infrastructure Holdings Ltd (1038):企業の財務・戦略的SWOT分析
    CK Infrastructure Holdings Ltd (1038) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Votorantim SA:企業の戦略的SWOT分析
    Votorantim SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Petrol dd Ljubljana (PETG):企業の財務・戦略的SWOT分析
    Petrol dd Ljubljana (PETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Straumann Holding AG (STMN):企業の財務・戦略的SWOT分析
    Straumann Holding AG (STMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Rabigh Refining & Petrochemical Co (2380):企業の財務・戦略的SWOT分析
    Rabigh Refining & Petrochemical Co (2380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Aero Simulation, Inc.:企業の戦略・SWOT・財務情報
    Aero Simulation, Inc. - Strategy, SWOT and Corporate Finance Report Summary Aero Simulation, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nuo Therapeutics Inc (AURX):医療機器:M&Aディール及び事業提携情報
    Summary Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind the regenerative capacity of the human body to trigger natural healing. T …
  • Green Plains Inc.:企業の戦略・SWOT・財務情報
    Green Plains Inc. - Strategy, SWOT and Corporate Finance Report Summary Green Plains Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Emera Inc (EMA):企業の財務・戦略的SWOT分析
    Emera Inc (EMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Zoll Medical Corporation-医療機器分野:企業M&A・提携分析
    Summary ZOLL Medical Corporation (Zoll), a subsidiary of Asahi Kasei Corporation, is a provider of medical devices and software solutions for advance emergency care. The company designs, manufactures and markets resuscitation devices and systems used for resuscitation and acute critical care victims …
  • Anthem Inc (ANTM):企業の財務・戦略的SWOT分析
    Anthem Inc (ANTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Investcorp Bank BSc (INVCORP):企業の財務・戦略的SWOT分析
    Investcorp Bank BSc (INVCORP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆